Today, the Prin Fin. & Acct. Officer of GTx (NASDAQ: GTXI), Jason Shackelford, sold shares of GTXI for $176.3K.
Following Jason Shackelford’s last GTXI Sell transaction on January 09, 2018, the stock climbed by 7.8%. In addition to Jason Shackelford, one other GTXI executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Currently, GTx has an average volume of 719.4K. The Company has a Price to Book ratio of 16.8319.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions.
